Lead Product(s): Alpha1-Proteinase Inhibitor (Human)
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.